Porcine Vaccines Market is Growing Robustly with Zoetis Inc. Receiving the European Commission Approval for its CircoMax Myco Vaccine Indicated for Porcine Circovirus Type 2 (PCV2) and Mycoplasma Hyopneumoniae in Pigs

 

The term "porcine vaccines" refers to the vaccines developed and used in animals, rather than in humans. The purpose of porcine vaccines is to protect farm animals from things like bacterial and viral diseases. The problem is that a lot of the viruses and bacteria that affect humans aren't infectious to animals, so it's difficult to develop vaccines against them. The two major types of porcine vaccines are Bovine Adverse Genomeopathy (BAG) and Meningitis. The former vaccine is more commonly known as the Meningitis vaccination; the latter is the Bago vaccine. Both vaccines prevent harmful viruses in the animals' bloodstream. However, they do have a few differences in how they work

Increasing demand for pork worldwide is expected to drive growth of the global porcine vaccines market. According to the Organisation for Economic Co-operation and Development (OECD), the total pork consumption in OECD countries reached 23.0 kilogram/capita in 2019, increasing from 22.1 kilograms/capita in 2010. The rise in pork consumption is attributed to the rapidly growing population and rising disposable incomes in emerging economies. Porcine vaccines can improve growth performance of pigs and prevent the spread of porcine parvovirus, mastitis, and more. Hence, these factors are expected to drive growth of the global porcine vaccines market. Furthermore, continuous research and development activities for the innovation of vaccines are expected to propel the global porcine vaccines market growth in the near future.

High expenses of maintaining and handling storage conditions combined with concerns regarding reverse reaction from vaccines are expected to restrain growth of the global porcine vaccines market. However, proactive government initiatives to develop novel vaccines can provide major business opportunities for key competitors in the near future. Among regions, North America is expected to witness significant growth in the global porcine vaccines market. This is owing to increasing demand for animal protein and growing expenditure on animal health by farm owners. Europe is expected to register a robust growth rate, owing to increasing demand for animal-based food products and rising awareness regarding porcine health as well recent advancements in the field of biotechnology.

Major companies involved in the global porcine vaccines market are Bayer AG, Zoetis Inc., IDT Biologika GmbH, Vetoquinol, HIPRA, Merial, Ceva Sante Animale, Intervet Inc., Elanco, and Arko Laboratories Ltd.

For instance, in December 2020, Zoetis Inc. received the European Commission approval for CircoMax Myco, a vaccine for pigs against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae.